Lebeau J, Deprez L, Pintiaux A, Reuter G
BMJ Case Rep. 2025; 18(1.
PMID: 39828291
PMC: 11751604.
DOI: 10.1136/bcr-2024-263529.
Reuter G, Potorac I, De Herdt C, Ameryckx L, Brichant G, Froelich S
Brain Spine. 2025; 5():104154.
PMID: 39802864
PMC: 11721832.
DOI: 10.1016/j.bas.2024.104154.
AlDoheyan T, Del Bigio M
Free Neuropathol. 2024; 5:27.
PMID: 39473896
PMC: 11519963.
DOI: 10.17879/freeneuropathology-2024-5813.
Noda R, Kawashima M, Akabane A, Inoue T
J Neurosurg Case Lessons. 2024; 8(15).
PMID: 39378522
PMC: 11465344.
DOI: 10.3171/CASE24416.
Pinkawa M, Bostrom J, Temming S, Schafer A, Kovacs A, Bostrom A
Strahlenther Onkol. 2024; 201(2):191-196.
PMID: 38871938
DOI: 10.1007/s00066-024-02248-0.
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A
Pharmaceut Med. 2024; 38(2):145-156.
PMID: 38296916
PMC: 10948458.
DOI: 10.1007/s40290-023-00510-x.
Development and Growth of Intracranial Meningiomas in Transgender Women Taking Cyproterone Acetate as Gender-Affirming Progestogen Therapy: A Systematic Review.
Millward C, Keshwara S, Islim A, Jenkinson M, Alalade A, Gilkes C
Transgend Health. 2023; 7(6):473-483.
PMID: 36644118
PMC: 9829145.
DOI: 10.1089/trgh.2021.0025.
Spontaneous regression of a posterior fossa meningioma: A case report.
Takada M, Yanaka K, Nakamura K, Akimoto K, Takeda H, Ishikawa E
Surg Neurol Int. 2022; 13:334.
PMID: 36128130
PMC: 9479528.
DOI: 10.25259/SNI_429_2022.
Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
Samoyeau T, Provost C, Roux A, Legrand L, Dezamis E, Plu-Bureau G
J Neurooncol. 2022; 160(1):127-136.
PMID: 36066786
DOI: 10.1007/s11060-022-04124-2.
Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.
Devalckeneer A, Aboukais R, Faisant M, Bourgeois P, Quentin V, Maurage C
Neurosurg Rev. 2021; 45(2):1691-1699.
PMID: 34850321
DOI: 10.1007/s10143-021-01708-w.
Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population.
Aranda G, Halperin I, Gomez-Gil E, Hanzu F, Segui N, Guillamon A
Front Endocrinol (Lausanne). 2021; 12:718200.
PMID: 34659112
PMC: 8515285.
DOI: 10.3389/fendo.2021.718200.
Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
Malaize H, Samoyeau T, Zanello M, Roux A, Benzakoun J, Peeters S
J Neurooncol. 2021; 152(2):279-288.
PMID: 33449307
DOI: 10.1007/s11060-021-03696-9.
Possible Abscopal Effect Observed in Frontal Meningioma After Localized IMRT on Posterior Meningioma Resection Cavity Without Adjuvant Immunotherapy.
Golub D, Kwan K, Knisely J, Schulder M
Front Oncol. 2019; 9:1109.
PMID: 31681619
PMC: 6813201.
DOI: 10.3389/fonc.2019.01109.
Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: A report of two cases and a brief literature review.
Raj R, Korja M, Koroknay-Pal P, Niemela M
Surg Neurol Int. 2018; 9:109.
PMID: 29930875
PMC: 5991277.
DOI: 10.4103/sni.sni_22_18.
Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate.
Sys C, Kestelyn P
GMS Ophthalmol Cases. 2016; 5:Doc05.
PMID: 27625949
PMC: 5015623.
DOI: 10.3205/oc000027.
Spontaneous Regression of an Incidental Spinal Meningioma.
Yilmaz A, Kizilay Z, Sair A, Avcil M, Ozkul A
Open Access Maced J Med Sci. 2016; 4(1):128-30.
PMID: 27275345
PMC: 4884232.
DOI: 10.3889/oamjms.2016.005.
Regression of Intracranial Meningioma during Treatment with α1-Adrenoceptor Blocker.
Hoegestoel E, Berg-Johnsen J
J Neurol Surg Rep. 2016; 77(1):e62-5.
PMID: 27175325
PMC: 4863873.
DOI: 10.1055/s-0035-1571204.
Spontaneous regression together with increased calcification of incidental meningioma.
Hirota K, Fujita T, Akagawa H, Onda H, Kasuya H
Surg Neurol Int. 2014; 5:73.
PMID: 24949216
PMC: 4061579.
DOI: 10.4103/2152-7806.132957.